ETHNOFLOX-IV

100ML WITH CARTON

ETHNOFLOX-IV is a high-quality intravenous infusion containing Ofloxacin, a broad-spectrum antibiotic belonging to the fluoroquinolone class. It is designed to combat a wide range of bacterial infections by inhibiting bacterial DNA replication. Ideal for treating severe bacterial infections, this infusion ensures quick action and high bioavailability, making it an essential component in acute medical settings.

While ETHNOFLOX-IV is generally well-tolerated, potential side effects include:

• Nausea and vomiting

• Diarrhea

• Dizziness or lightheadedness

• Headache

• Allergic reactions such as rash, itching, or swelling

• Tendonitis or tendon rupture (rare)

• QT interval prolongation (rare)

• Administered intravenously by a healthcare professional in a hospital or clinical setting.

• The dosage and duration depend on the type and severity of the infection.

• Ensure adequate hydration during the treatment period.

• Monitor renal and liver function in patients with pre-existing conditions.
• Avoid unnecessary use to prevent antibiotic resistance.
• Prolonged use may result in secondary infections such as fungal overgrowth.

Avoid using ETHNOFLOX-IV in the following cases:

• Patients with hypersensitivity to Ofloxacin or other fluoroquinolones.
• Pregnant or breastfeeding women, unless absolutely necessary.
• Pediatric patients (below 18 years), as it may affect bone development.
• Patients with a history of tendon disorders or QT prolongation.

• Tendinitis and Tendon Rupture: Discontinue immediately if tendon pain or swelling occurs.
• Photosensitivity: Avoid direct sunlight or UV light exposure during therapy.
• Neurological Effects: Monitor for seizures or psychiatric effects in predisposed individuals.
• Cardiac Risks: Patients with cardiovascular disorders should be monitored for QT prolongation.
• Drug Resistance: Use only for bacterial infections to avoid resistance development.

• Adult Dose: Typically 200–400 mg every 12 hours intravenously, depending on the severity of the infection.
• Renal Impairment: Dosage adjustment is required for patients with impaired renal function (creatinine clearance < 50 mL/min).

• With Drugs:
  • Antacids or multivitamins containing magnesium, calcium, or aluminum may reduce Ofloxacin’s effectiveness.
  • Co-administration with NSAIDs may increase the risk of CNS side effects.
  • Potentiates the effects of anticoagulants like warfarin.
• With Food: Food does not significantly affect Ofloxacin absorption, but avoid dairy products during therapy.
• With Alcohol: Limit alcohol intake as it may exacerbate dizziness or drowsiness.

• Administer ETHNOFLOX-IV only under medical supervision.
• Complete the full course of therapy, even if symptoms improve early.
• Report any adverse effects to a healthcare provider immediately.
• Avoid alcohol consumption during treatment to prevent adverse effects.
• Do not self-administer; seek medical advice for proper usage.

• Composition: Ofloxacin Infusion IP

• Form: Intravenous Infusion

• Manufacturer: EthixElite Lifesciences

• Pack Size: 100 mL or as specified

• Clinical guidelines for the use of fluoroquinolones in bacterial infections.

• Product monograph and prescribing information for Ofloxacin Infusion IP.

• Recent studies on Ofloxacin’s efficacy and safety profile.